Camp Nine (CMPE) 3.0000 $CMPE
Camp Nine Inc. Announces Corporate Name Change To Relmada Therapeutics Inc.
PR Newswire - Wed Jul 09, 6:30AM CDT
Camp Nine, Inc., (OTCBB: CMPE), a Nevada corporation which conducts its operations through Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has changed its corporate name to Relmada Therapeutics, Inc. The name change began with the Nevada Secretary of State filings yesterday. The next steps include FINRA approval for a symbol change to match the new name. The name change will have no effect on the Company's share structure, corporate organization, business model operations, or corporate governance.
Relmada Therapeutics Files Shares Registration Statement
PR Newswire - Tue Jul 01, 6:45AM CDT
Camp Nine, Inc. (the "Company"

, which conducts its operations through Relmada Therapeutics, Inc. ("Relmada"

(OTCBB: CMPE), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed resale of shares of its common stock. The registration statement relating to these securities has been filed with the SEC, but has yet to become effective.
Relmada Therapeutics to Present at the 2014 BIO International Convention
PR Newswire - Thu Jun 19, 6:30AM CDT
Relmada Therapeutics, which currently conducts its operations through Camp Nine, Inc. (the "Company"

, (OTCBB: CMPE), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, Chief Executive Officer, will be presenting at the 2014 BIO International Convention on Thursday, June 26, at 9:30 AM. PDT. The presentation will take place in the Solana Beach room. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California.
Relmada Therapeutics Successfully Completes Offerings Totaling $28 Million In Connection With Going Public Transaction
PR Newswire - Mon Jun 16, 6:30AM CDT
Camp Nine, Inc. (the "Company"

, which conducts its operations through Relmada Therapeutics Inc. ("Relmada"

(OTCBB: CMPE), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has completed equity capital raises totaling gross proceeds of $28MM associated with a going-public transaction. The Company intends to change its name to Relmada Therapeutics, Inc. to better reflect its business operations. The funding was accomplished through two separate offerings; the first offering was consummated by Relmada and closed on May 15, 2014 for aggregate gross proceeds of approximately $15 million and the second offering was consummated by the Company after the acquisition of Relmada and closed on June 10, 2014 for aggregate gross proceeds of approximately $10.7 million. Laidlaw & Company (UK) Ltd. acted as the exclusive placement agent in both financings.